The Annals of Internal Medicine features a communique from the Karolinska Institutet in Sweden demonstrating that elevated levels of antiphospholipid antibodies may be found in patients with myocardial infarction without any autoimmune co-morbidity, published in Annals of Internal Medicine reports.
Dr. John Cush RheumNow
7 years 11 months ago
The ACR 2018 RheumNow Review is up! Watch it here https://t.co/jtAySYbpKR or listen on iTunes or SoundCloud https://t.co/BBcghpaLEP
"If radiation was a drug that could improve survival in the metastatic setting like that it would be millions and millions of dollars." -- James B. Yu, of Yale Cancer Center, discussing aggressive use of stereotactic body radiation therapy in oligometastatic cancer.*******************************************************
Dr. Cush and Dr. Pope: Rheumatoid Arthritis Discussion
Dr. Jack Cush and Dr. Janet Pope discuss RA studies and takeaways from the ACR/ARHP Annual Meeting in Chicago.
Dr. John Cush RheumNow
7 years 11 months ago
Data from >50K commercial and Medicare claims in RA patients shows the risk of VTE (DVT/PE) to No different comparing pts on tofacitinib vs TNFi (HR 1.33; 95% CI, 0.78-2.24). Abst L09 #ACR18 https://t.co/dafoEcl9pD
Dr. John Cush RheumNow
7 years 11 months ago
European Commission (EC) has approved a label update for Cosentyx (secukinumab), now allowing up to 300 mg dosing and also includes 24-week Xray data with inhibition of progression of joint damage in PsA https://t.co/S6d4XE75Ov
Dr. John Cush RheumNow
7 years 11 months ago
Matching the Reference Product is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi https://t.co/I8ydhjRlEL
Dr. Paul Sufka: Wearable Technology
Dr. Paul Sufka discusses wearable technology at the ACR/ARHP Annual Meeting in Chicago.
Leonard Calabrese LCalabreseDO
8 years ago
Pegloticase is clearly our most important agent in Pts with high uric Acid burdens - it’s Achilles heal is immunogenicity- it’s vital to demonstrate whether this simple Rx is as good as it seems & Kudos to Alaska RHEUMS!!!! #ACR18 @GoutEducation @GoutandYou @HealioRheum https://t.co/MDvukRqCCx
Daniel H Solomon DanielHSolomon
8 years ago
Persistent Opioid Use Among Injured Workers’ Compensation Claimants https://t.co/hsmeB3uCCr
Leonard Calabrese LCalabreseDO
8 years ago
My top3 takeaways from #ACR18 1 PROs are a creative disruptive force and we need them in practice 2. JAKs should move up in our Rx priorities 3. IrAEs are an area of unmet educational need!! @HealioRheum @RheumNow @AWIRGROUP @rheumnews1 @psufka
More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.
This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups. ACR 2018 highlights for me included:
